Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker's high-performance scienti c instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with its customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular research, in applied and pharma applications, in microscopy and nanoanalysis, and in industrial applications, as well as in cell biology, preclinical imaging, clinical phenomics and proteomics research and clinical microbiology.
40 Manning Rd
Billerica, Massachusetts 01821-3915
Phone: 19786633660
www.bruker.com
https://www.investing.com/news/company-news/bruker-corp-announces-board-member-resignation-93CH-3560114
The latest update is out from Bruker (BRKR). Dr. Philip Ma has resigned from the board of directors of Bruker Corporation to focus on his business,…
Bruker makes strategic investment in NovAliX, a drug discovery CRO in France, to accelerate growth and innovation in biophysics methods.
NovAliX is a drug discovery focused CRO with award-winning chemistry teams and one of the world''s most comprehensive biophysics platforms. Bruker and NovAliX intend to collaborate on enabling new …
Bruker invests in NovAliX, boosting drug discovery capabilities. Partnership focuses on advanced biophysical methods, aiming to accelerate development of new medicines. Explore the impact on pharmaceutical research.
The London Company, an investment management company, released “The London Company Mid Cap Strategy” second quarter 2024 investor letter. A copy of the letter can be downloaded here. US markets posted mixed results in 2024. The portfolio fell 5.9% (6%.0 net) during the quarter compared to a 3.4% decrease for the Russell Midcap Index. Both stock […]
Bruker (NASDAQ: BRKR ) just reported results for the second quarter of 2024. Bruker reported earnings per share of 52 cents. This was below the analyst estimate for EPS of 54 cents. The company reported revenue of $800.70 million. This was 0.96% better than the analyst estimate for revenue of $793.10 million. InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at editor@investorplace.com. More From InvestorPlace Legendary Investor Predicts: “Forget AI… THIS Technology Is the Future” The post BRKR Stock Earnings: Bruker Misses EPS, Beats Revenue for Q2 2024 appeared first on InvestorPlace .
Bruker Corporation (Nasdaq: BRKR) today announced financial results for its second quarter and for the six months ended June 30, 2024. Frank H. Laukien, Bruker’s President and CEO, commented: “Our teams delivered excellent revenue growth in the second quarter and a solid first half of 2024, despite soft general market conditions. Our well above-market organic growth is driven by Bruker’s Jetzt den vollständigen Artikel lesen
The patent at issue was ruled invalid by the German Federal Patent Court in May 2024 Bruker Corporation (Nasdaq: BRKR) today announced that it has posted a bond, as authorized by the Munich Higher…
Bruker Corporation (Nasdaq: BRKR) today announced that it has posted a bond, as authorized by the Munich Higher Regional Court, in order to suspend an injunction that had been impacting sales of CosMx Spatial Molecular Imager (SMI) products by its NanoString business in Germany. This development is connected with ongoing patent litigation with 10x Genomics, during an appeal process in Germany. Jetzt den vollständigen Artikel lesen